3
Nov
Zymergen ditches thin-film program, targets agriculture, vaccines, drugs
Following a $575 million IPO in April, the company’s once-lofty prospects blew up after its bio-manufactured thin film for smart phones didn’t play nicely with its customers processes.
Source: Arizona Business Journal
